Israele - inglese - Ministry of Health

j-c health care ltd - selexipag - film coated tablets - selexipag 1200 mcg - selexipag - uptravi is indicated for the long-term treatment of pulmonary arterial hypertension (pah) in adult patients with who functional class (fc) ii-iii, either as combination therapy in patients insufficiently controlled with an endothelin receptor antagonist (era) and/or a phosphodiesterase type 5 (pde-5) inhibitor, or as monotherapy in patients who are not candidates for these therapies.efficacy has been shown in a pah population including idiopathic and heritable pah, pah associated with connective tissue disorders, and pah associated with corrected simple congenital heart disease

Israele - inglese - Ministry of Health

j-c health care ltd - selexipag - film coated tablets - selexipag 1400 mcg - selexipag - uptravi is indicated for the long-term treatment of pulmonary arterial hypertension (pah) in adult patients with who functional class (fc) ii-iii, either as combination therapy in patients insufficiently controlled with an endothelin receptor antagonist (era) and/or a phosphodiesterase type 5 (pde-5) inhibitor, or as monotherapy in patients who are not candidates for these therapies.efficacy has been shown in a pah population including idiopathic and heritable pah, pah associated with connective tissue disorders, and pah associated with corrected simple congenital heart disease

Israele - inglese - Ministry of Health

j-c health care ltd - selexipag - film coated tablets - selexipag 1600 mcg - selexipag - uptravi is indicated for the long-term treatment of pulmonary arterial hypertension (pah) in adult patients with who functional class (fc) ii-iii, either as combination therapy in patients insufficiently controlled with an endothelin receptor antagonist (era) and/or a phosphodiesterase type 5 (pde-5) inhibitor, or as monotherapy in patients who are not candidates for these therapies.efficacy has been shown in a pah population including idiopathic and heritable pah, pah associated with connective tissue disorders, and pah associated with corrected simple congenital heart disease

Israele - inglese - Ministry of Health

j-c health care ltd - selexipag - film coated tablets - selexipag 200 mcg - selexipag - uptravi is indicated for the long-term treatment of pulmonary arterial hypertension (pah) in adult patients with who functional class (fc) ii-iii, either as combination therapy in patients insufficiently controlled with an endothelin receptor antagonist (era) and/or a phosphodiesterase type 5 (pde-5) inhibitor, or as monotherapy in patients who are not candidates for these therapies.efficacy has been shown in a pah population including idiopathic and heritable pah, pah associated with connective tissue disorders, and pah associated with corrected simple congenital heart disease

Israele - inglese - Ministry of Health

j-c health care ltd - selexipag - film coated tablets - selexipag 400 mcg - selexipag - uptravi is indicated for the long-term treatment of pulmonary arterial hypertension (pah) in adult patients with who functional class (fc) ii-iii, either as combination therapy in patients insufficiently controlled with an endothelin receptor antagonist (era) and/or a phosphodiesterase type 5 (pde-5) inhibitor, or as monotherapy in patients who are not candidates for these therapies.efficacy has been shown in a pah population including idiopathic and heritable pah, pah associated with connective tissue disorders, and pah associated with corrected simple congenital heart disease

Israele - inglese - Ministry of Health

j-c health care ltd - selexipag - film coated tablets - selexipag 600 mcg - selexipag - uptravi is indicated for the long-term treatment of pulmonary arterial hypertension (pah) in adult patients with who functional class (fc) ii-iii, either as combination therapy in patients insufficiently controlled with an endothelin receptor antagonist (era) and/or a phosphodiesterase type 5 (pde-5) inhibitor, or as monotherapy in patients who are not candidates for these therapies.efficacy has been shown in a pah population including idiopathic and heritable pah, pah associated with connective tissue disorders, and pah associated with corrected simple congenital heart disease

Israele - inglese - Ministry of Health

j-c health care ltd - selexipag - film coated tablets - selexipag 800 mcg - selexipag - uptravi is indicated for the long-term treatment of pulmonary arterial hypertension (pah) in adult patients with who functional class (fc) ii-iii, either as combination therapy in patients insufficiently controlled with an endothelin receptor antagonist (era) and/or a phosphodiesterase type 5 (pde-5) inhibitor, or as monotherapy in patients who are not candidates for these therapies.efficacy has been shown in a pah population including idiopathic and heritable pah, pah associated with connective tissue disorders, and pah associated with corrected simple congenital heart disease

Nuova Zelanda - inglese - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - selexipag 1000ug - film coated tablet - 1000 mcg - active: selexipag 1000ug excipient: carnauba wax hyprolose hypromellose disintergrant/low substituted hydroxypropyl cellulose iron oxide red iron oxide yellow magnesium stearate maize starch mannitol propylene glycol titanium dioxide - uptravi, is indicated for the treatment of: · idiopathic pulmonary arterial hypertension · heritable pulmonary arterial hypertension · pulmonary arterial hypertension associated with connective tissue disease · pulmonary arterial hypertension associated with congenital heart disease with repaired shunts · pulmonary arterial hypertension associated with drugs and toxins in patients with who functional class ii, iii or iv symptoms. uptravi is effective in combination with an endothelin receptor antagonist (era) or a phosphodiesterase-5 (pde-5) inhibitor, or in triple combination with an era and a pde-5 inhibitor, or as monotherapy.

Nuova Zelanda - inglese - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - selexipag 1200ug - film coated tablet - 1200 mcg - active: selexipag 1200ug excipient: carnauba wax hyprolose hypromellose disintergrant/low substituted hydroxypropyl cellulose iron oxide black iron oxide red magnesium stearate maize starch mannitol propylene glycol titanium dioxide - uptravi, is indicated for the treatment of: · idiopathic pulmonary arterial hypertension · heritable pulmonary arterial hypertension · pulmonary arterial hypertension associated with connective tissue disease · pulmonary arterial hypertension associated with congenital heart disease with repaired shunts · pulmonary arterial hypertension associated with drugs and toxins in patients with who functional class ii, iii or iv symptoms. uptravi is effective in combination with an endothelin receptor antagonist (era) or a phosphodiesterase-5 (pde-5) inhibitor, or in triple combination with an era and a pde-5 inhibitor, or as monotherapy.

Nuova Zelanda - inglese - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - selexipag 1400ug - film coated tablet - 1400 mcg - active: selexipag 1400ug excipient: carnauba wax hyprolose hypromellose disintergrant/low substituted hydroxypropyl cellulose iron oxide yellow magnesium stearate maize starch mannitol propylene glycol titanium dioxide - uptravi, is indicated for the treatment of: · idiopathic pulmonary arterial hypertension · heritable pulmonary arterial hypertension · pulmonary arterial hypertension associated with connective tissue disease · pulmonary arterial hypertension associated with congenital heart disease with repaired shunts · pulmonary arterial hypertension associated with drugs and toxins in patients with who functional class ii, iii or iv symptoms. uptravi is effective in combination with an endothelin receptor antagonist (era) or a phosphodiesterase-5 (pde-5) inhibitor, or in triple combination with an era and a pde-5 inhibitor, or as monotherapy.